Publications and communications of Audrey Neuprez

Neuprez, A., Kaux, J.-F., Locquet, M., Beaudart, C., & Reginster, J.-Y. (January 2021). The presence of erosive joints is a strong predictor of radiological progression in hand osteoarthritis: results of a 2-year prospective follow-up of the Liège Hand Osteoarthritis Cohort (LIHOC). Arthritis Research and Therapy, 23 (1), 12 (9. doi:10.1186/s13075-020-02390-x

DEROISY, R., NEUPREZ, A., LEONARD, Y., LECART, M.-P., MASSENET, V., GILLET, P., Reginster, J.-Y., & KAUX, J.-F. (December 2020). Identification, through a Fracture Liaison Service, of undiagnosed vertebral fractures in patients hospitalized for a prevalent hip fragility fracture. Osteoporosis International, 31 (S1), 200.

NEUPREZ, A., DEROISY, R., LEONARD, Y., LECART, M.-P., MASSENET, V., GILLET, P., KAUX, J.-F., & Reginster, J.-Y. (December 2020). Secondary fracture prevention in hip fracture patients: 6-year impact of a Fracture Liaison Service. Osteoporosis International, 31 (S1), 199-200.

Conchin, A., Delvaux, F., Radermecker, R., NEUPREZ, A., Croisier, J.-L., & Kaux, J.-F. (September 2020). Impacts du sport de haut niveau sur le système locomoteur et endocrinien : état de la question. Journal de Traumatologie du Sport, 37 (3), 154-161. doi:10.1016/j.jts.2020.06.001

BETHLEN, S., Bornheim, S., Delvaux, F., Marquet, L., Pelzer, D., NEUPREZ, A., Lecart, M.-P., MAERTENS DE NOORDHOUT, B., WANG, F.-C., Tomasella, M., Croisier, J.-L., SERVAIS, D., GÖBELS, C., & Kaux, J.-F. (May 2020). Innovations en médecine physique et réadaptation. Revue Médicale de Liège, 75 (5-6), 445-451.

Neuprez, A., Neuprez, A., KAUX, J.-F., KURTH, W., DANIEL, C., THIRION, T., Hustin, J.-P., Gillet, P., Bruyère, O., & Reginster, J.-Y. (March 2020). Total joint replacement improves pain, functional quality of life, and health utilities in patients with late-stage knee and hip osteoarthritis for up to 5 years. Clinical Rheumatology, 39 (3), 861-871. doi:10.1007/s10067-019-04811-y

Kaux, J.-F., LECART, M.-P., & NEUPREZ, A. (19 January 2019). How to improve the care path of osteoporotic patients? [Paper presentation]. Belgian Bone Club Clinical Update Symposium, Brussels, Belgium.

Neuprez, A., Neuprez, A., KAUX, J.-F., KURTH, W., DANIEL, C., THIRION, T., HUSKIN, J.-P., Gillet, P., Bruyère, O., & Reginster, J.-Y. (April 2018). Early Clinically Relevant Improvement in Quality of Life and Clinical Outcomes 1 Year Postsurgery in Patients with Knee and Hip Joint Arthroplasties. Cartilage, 9 (2), 127-139. doi:10.1177/1947603517743000

Neuprez, A., Neuprez, A., Maheu, E., Bruyère, O., Kaux, J.-F., & Reginster, J.-Y. (April 2018). Determinants of clinical and radiological progression of hand osteoarthritis over 2 years. Osteoporosis International, 29 S1, 438.

Kaux, J.-F., & Neuprez, A. (15 March 2018). Actualités thérapeutiques dans le traitement de la gonarthrose [Paper presentation]. Actualité Thérapeutique dans le Traitement de la Gonarthrose.

Neuprez, A., Neuprez, A., KURTH, W., Gillet, P., Bruyère, O., & Reginster, J.-Y. (2018). Profile of osteoarthritic patients undergoing hip or knee arthroplasty, a step toward a definition of the “need for surgery”. Aging Clinical and Experimental Research, 30, 315-321. doi:10.1007/s40520-017-0780-1

Neuprez, A., KURTH, W., GILLET, P., Bruyère, O., & Reginster, J.-Y. (March 2017). Profile of osteoarthritic patients undergoing total hip and knee arthroplasty. Osteoporosis International, 28 Suppl 1, 252.

Hiligsmann, M., Neuprez, A., Buckinx, F., Locquet, M., & Reginster, J.-Y. (2017). A scoping review of the public health impact of vitamin D - fortified dairy products for fracture prevention. Archives of Osteoporosis, 12, 57. doi:10.1007/s11657-017-0352-1

Neuprez, A., Delcour, J.-P., Fatemi, F., Gillet, P., Crielaard, J.-M., Bruyère, O., & Reginster, J.-Y. (15 December 2016). Patients' expectations impact their satisfaction following total hip or knee arthroplasty. PLoS ONE, 11 (12), 1-14. doi:10.1371/journal.pone.0167911

Neuprez, A., KURTH, W., THIRION, T., DANIEL, C., HUSKIN, J.-P., GILLET, P., Bruyère, O., & Reginster, J.-Y. (April 2016). Age-standardized quality of life after hip or knee arthoplasty. Osteoporosis International, 27 (Supplement 1), 541-542.

Neuprez, A., Bruyère, O., Dardenne, N., Distèche, S., Maheu, E., Burlet, N., & Reginster, J.-Y. (March 2015). Assessment and determinants of aesthetic discomfort in hand osteoarthritis: The Liège Hand Osteoarthritis Cohort (LICOH). Osteoporosis International, 26 (S1), 43-S44.

Neuprez, A., Bruyère, O., Dardenne, N., DISTECHE, S., MAHEU, E., BURLET, N., D'HOOGHE, P., & Reginster, J.-Y. (2015). Assessment and determinants of aesthetic discomfort in hand osteoarthritis. Annals of the Rheumatic Diseases, 74, 1942. doi:10.1136/annrheumdis-2015-207718

NEUPREZ, A., Bruyère, O., Dardenne, N., DISTECHE, S., Maheu, E., Burlet, N., & Reginster, J.-Y. (2015). Baseline characteristics of the Liège Hand Osteoarthritis Cohort (LIHOC). Annals of the Rheumatic Diseases, 74 (Supp2), 1346. doi:10.1136/annrheumdis-2015-eular.3393

Neuprez, A., Bruyère, O., Dardenne, N., DISTECHE, S., Maheu, E., Burlet, N., & Reginster, J.-Y. (2015). Baseline characteristics of the Liège hand osteoarthritis cohort (LIHOC). Osteoporosis International, 26 (S1), 167.

Neuprez, A., Bruyère, O., Dardenne, N., DISTECHE, S., Maheu, E., Burlet, N., & Reginster, J.-Y. (2015). Assessment and determinants of aesthetic discomfort in hand osteoarthritis: the LIège Hand Osteoarthritis Cohort (LIHOC). Annals of the Rheumatic Diseases, 74 (Supp2), 110. doi:10.1136/annrheumdis-2015-eular.2778

Neuprez, A., Bruyère, O., MAHEU, E., Dardenne, N., Burlet, N., D'HOOGHE, P., DISTECHE, S., & Reginster, J.-Y. (2015). Aesthetic discomfort in hand osteoarthritis: results from the LIège Hand Osteoarthritis Cohort (LIHOC). Arthritis Research and Therapy, 17, 346. doi:10.1186/s13075-015-0807-y

NEUPREZ, A., Delcour, J.-P., Fatemi, F., GILLET, P., Mawet, M., François, G., Bruyère, O., CRIELAARD, J.-M., Gosset, C., & Reginster, J.-Y. (2015). Development and validation of the French version of a tool assessing patient's expectations in lower limb osteoarthritis. Journal of Orthopaedics, 12, 46-57. doi:10.1016/j.jor.2014.06.002

Reginster, J.-Y., NEUPREZ, A., LECART, M.-P., Beaudart, C., Buckinx, F., Slomian, J., & Bruyère, O. (2015). Ostéoporose et Médecine Personnalisée. Revue Médicale de Liège, 70 (5-6), 321-324.

NEUPREZ, A., Coste, S., Rompen, E., Crielaard, J.-M., & REGINSTER, J.-Y. (2014). Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab. Osteoporosis International, 25, 393-395. doi:10.1007/s00198-013-2437-z

NEUPREZ, A., François, G., KURTH, W., THIRION, T., DANIEL, C., HUSKIN, J.-P., Gillet, P., & Reginster, J.-Y. (2014). Radiological and clinical profile of osteoarthritis patients undergoing total knee replacement surgery. Osteoporosis International, 25 (2), 358.

NEUPREZ, A., François, G., KURTH, W., THIRION, T., DANIEL, C., HUSKIN, J.-P., & Reginster, J.-Y. (2014). Quality of life benefits of knee arthroplasty for osteoarthritis. Osteoporosis International, 25 (2), 40.

NEUPREZ, A., Rompen, E., Crielaard, J.-M., & Reginster, J.-Y. (2014). Teriparatide Therapy for Denosumab-Induced Osteonecrosis of the Jaw in a Male Osteoporotic Patient. Calcified Tissue International, 95, 94-96. doi:10.1007/s00223-014-9858-3

Reginster, J.-Y., NEUPREZ, A., Beaudart, C., Buckinx, F., Slomian, J., Distèche, S., & Bruyère, O. (2014). Bone forming agents for the management of osteoporosis. Panminerva Medica, 56 (2), 97-114.

Reginster, J.-Y., NEUPREZ, A., Beaudart, C., LECART, M.-P., Sarlet, N., Bernard, D., Distèche, S., & Bruyère, O. (2014). Antiresorptive Drugs Beyond Bisphosphonates and Selective Oestrogen Receptor Modulators for the Management of Postmenopausal Osteoporosis. Drugs and Aging, 31, 413-424. doi:10.1007/s40266-014-0179-z

Reginster, J.-Y., NEUPREZ, A., Dardenne, N., Beaudart, C., & Bruyère, O. (2014). Efficacy and safety of currently marketed anti-osteoporosis medications. Best Practice and Research. Clinical Endocrinology and Metabolism, 28, 809-34. doi:10.1016/j.beem.2014.09.003

Reginster, J.-Y., NEUPREZ, A., LECART, M.-P., Sarlet, N., Distèche, S., & Bruyère, O. (2014). Traitement de l'osteoporose post-menopausique: quoi de neuf en 2014? Revue Médicale de Liège, 69 (7-8), 441-53.

Bruyère, O., Hiligsmann, M., Zegels, B., NEUPREZ, A., & Reginster, J.-Y. (September 2013). Risk of hip fracture in community-dwelling and institutionalized osteoporotic patients: A 3-year study. International Journal of Gerontology, 7 (3), 167-70. doi:10.1016/j.ijge.2012.11.015

Bruyère, O., Fossi, M., Zegels, B., LEONORI, L., Hiligsmann, M., Neuprez, A., & Reginster, J.-Y. (April 2013). Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX criteria. Rheumatology International, 33 (4), 973-8. doi:10.1007/s00296-012-2460-y

NEUPREZ, A., François, G., Delcour, J., Fatemi, F., Bruyère, O., Gosset, C., Mancuso, C., Gillet, P., & Reginster, J.-Y. (April 2013). Validity of the French hip and knee replacement expectations surveys. Osteoporosis International, 24 (Suppl.1), 374.

NEUPREZ, A., Delcour, J., Fatemi, F., GILLET, P., Mawet, M., François, G., Bruyère, O., Crielaard, J.-M., Gosset, C., & Reginster, J.-Y. (2013). Développement et validation de la version française d'un questionnaire traitant des attentes des patients dans l'arthrose des membres inférieurs. Revue du Rhumatisme, 80 (S1), 181.

REGINSTER, J.-Y., Beaudart, C., NEUPREZ, A., & Bruyère, O. (2013). Strontium ranelate in the treatment of knee osteoarthritis: new insights and emerging clinical evidence. Therapeutic Advances in Musculoskeletal Disease, 5 (5), 268-276. doi:10.1177/1759720X13500862

NEUPREZ, A., WANG, F.-C., & CRIELAARD, J.-M. (23 November 2012). Case report: Traumatic injury of the spinal accessory nerve [Paper presentation]. Annual Congress of SPRM, Gent, Belgium.

BETHLEN, S., NEUPREZ, A., Maystadt, I., & WANG, F.-C. (22 November 2012). Usefulness of electrophysiology in muscle channelopathies [Paper presentation]. Annual Congress of SPRM, Gent, Belgium.

REGINSTER, J.-Y., Neuprez, A., LECART, M.-P., SARLET, N., & Bruyère, O. (October 2012). Role of glucosamine in the treatment for osteoarthritis. Rheumatology International, 32 (10), 2959-67. doi:10.1007/s00296-012-2416-2

Bruyère, O., Ethgen, O., Neuprez, A., Zegels, B., Gillet, P., HUSKIN, J.-P., & Reginster, J.-Y. (2012). Health-related quality of life after total knee or hip replacement for osteoarthritis: a 7-year prospective study. Archives of Orthopaedic and Trauma Surgery. doi:10.1007/s00402-012-1583-7

Neuprez, A., François, G., Bruyère, O., Kovats, V., KURTH, W., HUSKIN, J.-P., GILLET, P., & Reginster, J.-Y. (June 2012). Radiological and clinical profil of osteoarthritic patients undergoing of total joint replacement. Annals of the Rheumatic Diseases, 71 (Suppl.3), 693.

Neuprez, A., François, G., Bruyère, O., Kovats, V., THIRION, T., VAN CAUWENBERGE, H., DANIEL, C., GILLET, P., & Reginster, J.-Y. (June 2012). Assessment of quality of life in patients undergoing total joint replacement for OA of the lower limb. Annals of the Rheumatic Diseases, 71 (Suppl.3), 693.

Neuprez, A., François, G., Bruyère, O., Kovats, V., KURTH, W., HUSKIN, J.-P., Gillet, P., & Reginster, J.-Y. (March 2012). Radiological and clinical profil of osteoarthritic patients undergoing of total joint replacement. Osteoporosis International, 23 (Suppl. 2), 129-130.

NEUPREZ, A., François, G., Bruyère, O., Kovats, V., KURTH, W., HUSKIN, J.-P., GILLET, P., & Reginster, J.-Y. (2012). Evolution temporelle du profil clinique des patients arthrosiques allant bénéficier d’une arthroplastie de hanche ou de genou. Revue du Rhumatisme, 79 (S1), 272.

NEUPREZ, A., François, G., Bruyère, O., Kovats, V., THIRION, T., Van Cauwenberghe, H., DANIEL, C., GILLET, P., & Reginster, J.-Y. (2012). Profils clinique et radiologique des patients arthrosiques allant bénéficier d'une arthroplastie de hanche ou de genou. Revue du Rhumatisme, 79 (S1), 272.

Bruyère, O., Hiligsmann, M., Zegels, B., Neuprez, A., & Reginster, J.-Y. (March 2011). Risk of hip fracture in community-dwelling and institutionalized osteoporotic patients: a 3-year study. Osteoporosis International, 22 (Suppl.1), 332-333.

Bruyère, O., Neuprez, A., Fossi, M., Zegels, B., LEONORI, L., Hiligsmann, M., & Reginster, J.-Y. (March 2011). Reimbursement of drugs against osteoporosis based on FRAX® instead of the current criteria would reduce by 30% the cost (in a societal perspective) of anti-osteoporosis treatment in Belgium. Osteoporosis International, 22 (Suppl.1), 333-334.

Johansson, H., Kanis, J. A., McCloskey, E. V., Oden, A., Devogelaer, J. P., Kaufman, J. M., Neuprez, A., Hiligsmann, M., Bruyère, O., & Reginster, J.-Y. (2011). A FRAX(R) model for the assessment of fracture probability in Belgium. Osteoporosis International, 22 (2), 453-61. doi:10.1007/s00198-010-1218-1

Bruyère, O., Ethgen, O., Neuprez, A., Zegels, B., Gillet, P., Huskin, J.-P., & Reginster, J.-Y. (November 2010). Etude de la qualité de vie après la mise en place d’une prothèse de hanche ou de genou pour cause d’arthrose : une étude de cohorte avec un suivi de 7 ans. Revue du Rhumatisme, 77 (Suppl.3), 141.

Bruyère, O., Hiligsmann, M., Zegels, B., Neuprez, A., & Reginster, J.-Y. (November 2010). Résider en institution : un facteur de risque indépendant de fractures de hanche ? Une étude prospective d’une durée de 3 ans. Revue du Rhumatisme, 77 (Suppl.3), 67-68.

Bruyère, O., Neuprez, A., Fossi, M., Beaudart, C., Zegels, B., Leonori, L., Hiligsmann, M., & Reginster, J.-Y. (November 2010). Le remboursement des traitements contre l'ostéoporose basé sur l'utilisation de l'outil FRAX plutôt que sur les critères actuels permettrait de réduire de 30% le coût, dans une perspective sociétale, du traitement de l'ostéoporose en Belgique. Revue du Rhumatisme, 77 (Suppl.3), 66-67.

Reginster, J.-Y., & Neuprez, A. (November 2010). Strontium ranelate: a look back at its use for osteoporosis. Expert Opinion on Pharmacotherapy, 11 (17), 2915-2927. doi:10.1517/14656566.2010.533170

Bruyère, O., Vanoverberghe, M., Neuprez, A., Ethgen, O., Zegels, B., Gillet, P., Huskin, J.-P., & Reginster, J.-Y. (June 2010). Health-related quality of life after total knee or hip replacement: a 7-year prospective study. Annals of the Rheumatic Diseases, 69 (Suppl.3), 469.

Bruyère, O., Vanoverberghe, M., Neuprez, A., Ethgen, O., Zegels, B., Gillet, P., Huskin, J.-P., & Reginster, J.-Y. (May 2010). Health-related quality of life after total knee or hip replacement : a 7-year prospective study. Osteoporosis International, 21 (Suppl.1), 26.

Neuprez, A., Johansson, H., Kanis, J., McCloskey, E. V., Oden, A., Bruyère, O., Hiligsmann, M., Devogelaer, J., Kaufman, J., & Reginster, J.-Y. (May 2010). A FRAX® model for the assessment of fracture probability in Belgium. Osteoporosis International, 21 (Suppl.1), 255.

SCHOLTISSEN, S., Bruyère, O., Neuprez, A., Severens, H., Herrero-Beaumont, G., Rovati, L., Hiligsmann, M., & Reginster, J.-Y. (May 2010). Cost-effectiveness of glucosamine sulfate compared to acetaminophen in the treatment of knee osteoarthrits: a French health care perspective. Osteoporosis International, 21 (Suppl.1), 167.

Reginster, J.-Y., Neuprez, A., Hiligsmann, M., & Bruyère, O. (February 2010). Oral calcitonin in the management of osteoarthritis: hope or fantasy ? International Journal of Clinical Rheumatology, 5 (1), 53-58. doi:10.2217/ijr.09.68

Hiligsmann, M., Vanoverberghe, M., Neuprez, A., Bruyère, O., & Reginster, J.-Y. (2010). Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis. Expert Review of Pharmacoeconomics and Outcomes Research, 10 (4), 359-366. doi:10.1586/erp.10.53

Neuprez, A., & Reginster, J.-Y. (2010). Prevention and treatment of postmenopausal osteoporosis. In R. Rizzoli (Ed.), Atlas of postmenopausal osteoporosis (Third edition, pp. 83-114). London, United Kingdom: Current Medicine Group Publ.

SCHOLTISSEN, S., Bruyère, O., NEUPREZ, A., Severens, J. L., Herrero-Beaumont, G., Rovati, L., Hiligsmann, M., & Reginster, J.-Y. (2010). Glucosamine sulphate in the treatment of knee osteoarthritis: cost-effectiveness comparison with paracetamol. International Journal of Clinical Practice, 64 (6), 756-62. doi:10.1111/j.1742-1241.2010.02362.x

Neuprez, A., Johansson, H., Kanis, J., McCloskey, E. V., Oden, A., Bruyère, O., Hiligsmann, M., Devogelaer, J.-P., Kaufmann, J.-M., & Reginster, J.-Y. (December 2009). Rationalisation du remboursement des médicaments de l'ostéoporose : de la mesure isolée de la densité osseuse à l’intégration des facteurs cliniques de risque fracturaire. Validation de l’algorithme FRAX®. Revue Médicale de Liège, 64 (12), 612-619.

Bruyère, O., COLLETTE, J., DEROISY, R., Rabenda, V., Neuprez, A., Hiligsmann, M., & Reginster, J.-Y. (October 2009). Biochemical markers of bone and cartilage remodelling: interest in the prediction of lumbar disc degeneration progression and effects of strontium ranelate over a 3-year period. Arthritis and Rheumatism, 60 (number 10 (suppl.)), 313.

Hiligsmann, M., Neuprez, A., Scholtissen, S., & Reginster, J.-Y. (March 2009). Cost-effectiveness of strontium ranelate versus intravenous ibandronate in the treatment of postmenopausal women. Osteoporosis International, 20 (S1), 130.

Reginster, J.-Y., Devogelaer, J.-P., Hiligsmann, M., Kaufman, J.-M., Neuprez, A., Johansson, H., & Kanis, J. A. (March 2009). FRAX(r) and the assessment of fracture probability in men and women from Belgium. Osteoporosis International, 20 (Suppl.1), 38-39.

Scholtissen, S., Bruyère, O., Hiligsmann, M., Neuprez, A., Herrero-Beaumont, G., Rovati, L., & Reginster, J.-Y. (March 2009). Glucosamine sulfate in the treatment of knee osteoarthritis: impact on health utility. Osteoporosis International, 20 (Suppl.1), 149.

Scholtissen, S., Bruyère, O., Hiligsmann, M., Neuprez, A., Pavelka, K., Rovati, L., & Reginster, J.-Y. (March 2009). Effect of glucosamine sulfate on health utility data in patients with knee osteoarthritis : reanalysis of two 3-year prospective studies. Osteoporosis International, 20 (Suppl.1), 18.

Bruyère, O., DeCock, C., Mottet, C., Neuprez, A., MALAISE, O., & Reginster, J.-Y. (2009). Low dietary calcium in European postmenopausal osteoporotic women. Public Health Nutrition, 12 (1), 111-114. doi:10.1017/S1368980008002024

Bruyère, O., Scholtissen, S., Neuprez, A., Hiligsmann, M., & Reginster, J.-Y. (2009). Effets du sulfate de chondroitine sur les indices d'utilité de santé chez des sujets gonarthrosiques et analyses économiques préliminaires. Revue du Rhumatisme, 76, 1051.

Bruyère, O., SCHOLTISSEN, S., NEUPREZ, A., Hiligsmann, M., Toukouki, A., & Reginster, J.-Y. (2009). Impact of chondroitin sulphate on health utility in patients with knee osteoarthritis: towards economic analysis. Journal of Medical Economics, 12 (4), 356-360. doi:10.3111/13696990903438617

Bruyère, O., Scholtissen, S., Neuprez, A., Severens, H., Herrero-Beaumont, G., Rovati, L., Hiligsmann, M., & Reginster, J.-Y. (2009). Analyses coût-efficacité du sulfate de glucosamine chez des patients gonarthrosiques : comparaison avec le paracétamol. Revue du Rhumatisme, 76, 1097.

NEUPREZ, A., Hiligsmann, M., Bruyère, O., & Reginster, J.-Y. (2009). Efficacite anti-fracturaire de l'ibandronate administre par voie intraveineuse: de la complexite des etudes epidemiologiques interventionnelles a la pratique quotidienne. Revue Médicale de Liège, 64 (10), 525-9.

Neuprez, A., Johansson, H., Kanis, J., Mc Closkey, E., Oden, A., Bruyère, O., Hiligsmann, M., Devogelaer, J.-P., Kaufman, J.-M., & Reginster, J.-Y. (2009). Rationalisation du remboursement des médicaments de l'ostéoporose : de la mesure isolée de la densité osseuse à l'intégration des facteurs cliniques de risque fracturaire. Validation de l'algorithme FRAX(r). Revue du Rhumatisme, 76, 1070-1.

Reginster, J.-Y., Deroisy, R., NEUPREZ, A., Hiligsmann, M., Zegels, B., & Bruyère, O. (2009). Strontium ranelate: new data on fracture prevention and mechanisms of action. Current Osteoporosis Reports, 7 (3), 96-102. doi:10.1007/s11914-009-0016-1

Reginster, J.-Y., Hiligsmann, M., Rabenda, V., Zegels, B., Neuprez, A., & Bruyère, O. (2009). Ibandronate in the management of postmenopausal osteoporosis. Clinical Medicine. Therapeutics, 1, 1409-1421.

Reginster, J.-Y., Collette, J., NEUPREZ, A., Zegels, B., Deroisy, R., & Bruyère, O. (10 February 2008). Role of Biochemical Markers of Bone Turnover as Prognostic Indicator of Successful Osteoporosis Therapy. BONE, 42, 832-836. doi:10.1016/j.bone.2008.01.021

Reginster, J.-Y., Collette, J., Neuprez, A., & Bruyère, O. (2008). Strontium ranelate in the management of spinal and peripheral osteoporosis. Review of Endocrinology, 26-33.

Malaise, O., Neuprez, A., & Reginster, J.-Y. (2008). Traitements non hormonaux de l’ostéoporose postménopausique. Gynécologie Obstétrique et Fertilité, 36, 815-822. doi:10.1016/j.gyobfe.2007.05.026

NEUPREZ, A., Hiligsmann, M., Scholtissen, S., Bruyère, O., & Reginster, J.-Y. (2008). Strontium ranelate: The first agent of a new therapeutic class in osteoporosis. Advances in Therapy, 25 (12), 1235-56. doi:10.1007/s12325-008-0125-8

NEUPREZ, A., & Reginster, J.-Y. (2008). Bone-forming agents in the management of osteoporosis. Best Practice and Research. Clinical Endocrinology and Metabolism, 22 (5), 869-83. doi:10.1016/j.beem.2008.06.003

Reginster, J.-Y., NEUPREZ, A., & Bruyère, O. (2008). Ibandronate in profile: drug characteristics and clinical efficacy. Expert Opinion on Drug Metabolism and Toxicology, 4 (7), 941-51. doi:10.1517/17425255.4.7.941

Bruyère, O., Malaise, O., NEUPREZ, A., Collette, J., & Reginster, J.-Y. (August 2007). Prevalence of vitamin D inadequacy in European postmenopausal women. Current Medical Research and Opinion, 23 (8), 1939-1944. doi:10.1185/030079907X219562

Reginster, J.-Y., Bruyère, O., & NEUPREZ, A. (May 2007). Current role of glucosamine in the treatment of osteoarthritis. Rheumatology, 46 (5), 731-735. doi:10.1093/rheumatology/kem026

Neuprez, A., Bruyère, O., Collette, J., & Reginster, J.-Y. (26 April 2007). Vitamin D inadequacy in Belgian postmenopausal osteoporotic women. BMC Public Health, 7 (147), 64. doi:10.1186/1471-2458-7-64

Bruyère, O., De Cock, C., Neuprez, A., MALAISE, O., & Reginster, J.-Y. (March 2007). Calcium daily food intake is very low in European postmenopausal women. Osteoporosis International, 18 (Suppl.1), 125.

Bruyère, O., MALAISE, O., Neuprez, A., Collette, J., & Reginster, J.-Y. (March 2007). Prevalence of vitamin D inadequacy is high in European postmenopausal women. Osteoporosis International, 18 (Suppl.1), 124.

Neuprez, A., Bruyère, O., & Reginster, J.-Y. (March 2007). Vitamin D inadequacy in Belgian postmenopausal women. Osteoporosis International, 18 (Suppl.1), 123.

Reginster, J.-Y., Malaise, O., NEUPREZ, A., & Bruyère, O. (February 2007). Strontium ranelate in the prevention of osteoporotic fractures. International Journal of Clinical Practice, 61 (2), 324-328. doi:10.1111/j.1742-1241.2006.01249.x

Neuprez, A., Hiligsmann, M., Bruyère, O., Ethgen, O., & Reginster, J.-Y. (2007). Prevention of hip fractures in osteoporosis. Minerva Ortopedica e Traumatologica, 58 (5), 423-437.

Reginster, J.-Y., Malaise, O., NEUPREZ, A., Jouret, V. E., & Close, P. (2007). Intermittent bisphosphonate therapy in postmenopausal osteoporosis - Progress to date. Drugs and Aging, 24 (5), 351-359. doi:10.2165/00002512-200724050-00001

Bruyère, O., MALAISE, O., Neuprez, A., Collette, J., & Reginster, J.-Y. (December 2006). Prévalence élevée de la carence en vitamine D chez la femme ménopausée en Europe et principalement en France : analyse d'une cohorte de 8532 sujets. Revue du Rhumatisme, 73, 1052.

Bruyère, O., MALAISE, O., Neuprez, A., COLLETTE, J., & Reginster, J.-Y. (November 2006). European postmenopausal osteoporotic women have high prevalence of vitamin D inadequacy. Arthritis and Rheumatism, 54 (Suppl), 585.

Close, P., NEUPREZ, A., & Reginster, J.-Y. (August 2006). Developments in the pharmacotherapeutic management of osteoporosis. Expert Opinion on Pharmacotherapy, 7 (12), 1603-1615. doi:10.1517/14656566.7.12.1603

Bruyère, O., MALAISE, O., Neuprez, A., & Reginster, J.-Y. (June 2006). Young postmenopausal women have high prevalence of inadequate serum vitamin D levels: results of a European study. Osteoporosis International, 17 (Suppl.2), 56.

Bruyère, O., MALAISE, O., Neuprez, A., & Reginster, J.-Y. (June 2006). High prevalence of inadequate serum vitamind D levels in osteoporotic European postmenopausal women. Osteoporosis International, 17 (Suppl.2), 33-34.

NEUPREZ, A., Gillet, P., Collette, C., & Reginster, J.-Y. (April 2006). L'osteodensitometrie dans le depistage de l'osteoporose: le paradoxe Belge. Revue Médicale de Liège, 61 (4), 249-55.

Reginster, J.-Y., Rabenda, V., & NEUPREZ, A. (April 2006). Adherence, patient preference and dosing frequency: Understanding the relationship. BONE, 38 (4 Suppl 1), 2-6. doi:10.1016/j.bone.2006.01.150

Bruyère, O., MALAISE, O., Neuprez, A., & Reginster, J.-Y. (March 2006). High prevalence of inadequate serum vitamind D levels in osteoporotic European postmenopausal women. Osteoporosis International, 17 (Suppl.1), 86.

Bruyère, O., MALAISE, O., Neuprez, A., & Reginster, J.-Y. (March 2006). Early postmenopausal women have high prevalence of inadequate serum vitamin D levels. Results of a European study. Osteoporosis International, 17 (Suppl.1), 85-86.

Bruyère, O., MALAISE, O., Neuprez, A., & Reginster, J.-Y. (March 2006). Calcium daily food intake in European post-menopausal women. Osteoporosis International, 17 (Suppl.1), 101.

Richy, F., Gourlay, M., Neuprez, A., Ethgen, O., Bruyère, O., & Reginster, J.-Y. (November 2003). Bone mineral density and vertebral fractures in women who have discontinued hormone replacement therapy: a retrospective population-based study. Osteoporosis International, 14 (Suppl. 7), 67.

Kvasz, A., Bruyère, O., Neuprez, A., & Reginster, J.-Y. (November 2002). Is there any rationale for prescribing hormone replacement therapy (HRT) to prevent or to treat osteoarthritis? Osteoporosis International, 13 (Suppl.3), 59.